SPRY2 and ovarian cancer: It should be noted in the present study that the expression of both Spry1 and Spry2 isoforms in OVCAR-3 cells was significantly higher than that in the other cancer cell lines and the control group, implying that although decreased expression of Spry1 and/or Spry2 was observed more frequently amongst the ovarian cancer cell lines studied, decline in the Spry expression might not necessarily be required in all epithelial ovarian cancers.